In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of gram-negative bacilli collected worldwide in 2014 to 2016

Antimicrobial Agents and Chemotherapy

Volumn 62, Issue 2, 2018, Pages

  Hackel, Meredith A ^a   Tsuji, Masakatsu ^b   Yamano, Yoshinori ^b   Echols, Roger ^c   Karlowsky, James A ^d   Sahm, Daniel F ^a  

^a Division of Microbiology   (United States)

^b SHIONOGI AND CO LTD   (Japan)

^c Clinical Development and Medical Affairs LLC   (United States)

^d UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Carbapenem nonsusceptible; Cefiderocol; Gram negative bacilli; Multidrug resistant; Siderophore

Indexed keywords

AMIKACIN; AVIBACTAM PLUS CEFTAZIDIME; CARBAPENEM; CEFEPIME; CEFIDEROCOL; CEFTOLOZANE PLUS TAZOBACTAM; CIPROFLOXACIN; COLISTIN; MEROPENEM; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; SIDEROPHORE;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; BURKHOLDERIA CEPACIA; CITROBACTER; CITROBACTER AMALONATICUS; CITROBACTER FREUNDII; CITROBACTER KOSERI; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; ENTEROBACTER; ENTEROBACTER AEROGENES; ENTEROBACTER ASBURIAE; ENTEROBACTER CLOACAE; ENTEROBACTER KOBEI; ENTEROBACTERIACEAE; ESCHERICHIA COLI; IN VITRO STUDY; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MIC50; MIC90; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; STENOTROPHOMONAS MALTOPHILIA; DRUG EFFECT; GRAM NEGATIVE BACTERIUM; HUMAN; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; SIDEROPHORES;

EID: 85040962574     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01968-17     Document Type: Article

References (37)

1. KPC into bacterial species beyond Klebsiella pneumoniae and in vitro susceptibility to ceftazidime-avibactam and aztreonam-avibactam. Antimicrob Agents Chemother 60:4490–4500. https://doi.org/10.1128/AAC.00107-16.
2. de Jonge BLM, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF, Nichols WW. 2016. In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM global surveillance study (2012 to 2014). Antimicrob Agents Chemother 60:3163–3169. https://doi.org/10.1128/AAC.03042-15.
3. Zilberberg MD, Kollef MH, Shorr AF. 2016. Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: a survey study. J Hosp Med 11:21–26. https://doi.org/10.1002/jhm.2477.
4. Labarca JA, Costa Sallas MJ, Seas C, Guzmàn-Blanco M. 2014. Carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter baumannii in the nosocomial setting in Latin America. Crit Rev Microbiol 42: 276 –292. https://doi.org/10.3109/1040841X.2014.940494.
5. Clinical and Laboratory Standards Institute. 2017. Performance standards for antimicrobial susceptibility testing; twenty-seventh informational supplement. CLSI document M100-S27. CLSI, Wayne, PA.
6. Biedenbach D, Bouchillon S, Hackel M, Hoban D, Kazmierczak K, Hawser S, Badal R. 2015. Dissemination of NDM metallo--lactamase genes among clinical isolates of Enterobacteriaceae collected during the SMART global surveillance study from 2008 to 2012. Antimicrob Agents Chemother 59:826 – 830. https://doi.org/10.1128/AAC.03938-14.
7. Walsh TR. 2010. Emerging carbapenemases: a global perspective. Int J Antimicrob Agents 36(Suppl 3):S8–S14. https://doi.org/10.1016/S0924-8579(10)70004-2.
8. Poirel L, Nordmann P. 2006. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 12: 826–836. https://doi.org/10.1111/j.1469-0691.2006.01456.x.
9. Brooke JS. 2012. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev 25:2–41. https://doi.org/10.1128/CMR.00019-11.
10. World Health Organization. 2014. Antimicrobial resistance global report on surveillance. World Health Organization, Geneva, Switzerland. http://www.who.int/drugresistance/documents/surveillancereport/en/.
11. Ito A, Nishikawa T, Matsumoto S, Yoshizawa H, Sato T, Nakamura R, Tsuji M, Yamano Y. 2016. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother 60:7396–7401.
12. Ito A, Nishikawa T, Oota M, Kanazawa S, Fukuhara N, Yamaguchi T, Nakamura R, Tsuji M, Yamano Y. 2015. S-649266, a novel siderophore cephalosporin: binding affinity to PBP and bactericidal activity, abstr ECCMID-1871. Abstr 25th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, 25 to 28 April 2015.
13. Kohira N, West J, Ito A, Ito-Horiyama T, Nakamura R, Sato T, Rittenhouse S, Tsuji M, Yamano Y. 2016. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother 60:729 –734. https://doi.org/10.1128/AAC.01695-15.
14. Ito-Horiyama T, Ishii Y, Ito A, Sato T, Nakamura R, Fukuhara N, Tsuji M, Yamano Y, Yamaguchi K, Tatedo K. 2016. Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases. Antimicrob Agents Chemother 60:4384 – 4386. https://doi.org/10.1128/AAC.03098-15.
15. Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, Rhomberg PR, Jones RN, Yoshizawa H, Nakamura R, Tsuji M, Yamano Y. 2016. In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. J Antimicrob Chemother 71:670–677. https://doi.org/10.1093/jac/dkv402.
16. Tsuji M, Ito A, Nakamura R, Yamano Y, Shimada J. 2014. S-649266, a novel siderophore cephalosporin: in vitro activity against Gram-negative bacteria. Open Forum Infect Dis 1(Suppl 1):S108. https://doi.org/10 .1093/ofid/ofu052.118.
17. Clinical and Laboratory Standards Institute. 2016. Subcommittee on Antimicrobial Susceptibility Testing, meeting minutes and presentations, January 2016. CLSI, Wayne, PA.
18. Clinical and Laboratory Standards Institute. 2017. Subcommittee on Antimicrobial Susceptibility Testing, meeting minutes and presentations, January 2017. CLSI, Wayne, PA.
19. Clinical and Laboratory Standards Institute. 2016. Subcommittee on Antimicrobial Susceptibility Testing, meeting minutes and presentations, June 2016. CLSI, Wayne, PA.
20. Otto BR, Verweij-van Vught AM, MacLaren DM. 1992. Transferrins and heme-compounds as iron sources for pathogenic bacteria. Crit Rev Microbiol 18:217–233. https://doi.org/10.3109/10408419209114559.
21. Tsuji M, Horiyama T, Toba S, Nakamura R, Yamano Y. 2015. S-649266, a novel siderophore cephalosporin: in vivo efficacy in murine infection model caused by multidrug-resistant gram-negative bacteria, abstr 0253. Abstr 25th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, 25 to 28 April 2015.
22. Tsuji M, Nakamura R, Hackel M, Sahm DF, Sato T, Echols R, Yamano Y. 2015. Use of iron-depleted cation-adjusted Mueller Hinton broth (ID-CAMHB) for microdilution testing of S-649266, a novel siderophore cephalosporin, abstr 0808. Abstr 25th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, 25 to 28 April 2015.
23. Ghazi I, Tsuji M, Nicolau DP. 2016. Activity of S-649266 siderophore cephalosporin and comparators against Pseudomonas aeruginosa in murine thigh infection model, abstr M-516. Abstr ASM Microbe 2016, Boston, MA, 16 to 20 June 2016. American Society of Microbiology, Washington, DC.
24. Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; tenth edition. Approved standard M07-A10. CLSI, Wayne, PA.
25. Ito A, Kohira N, Nakamura R, Tsuji M, Kreiswirth B, Yamano Y. 2015. S-649266, a novel siderophore cephalosporin: in vitro activity against gram-negative bacteria including carbapenem resistant strains, abstr 0252. Abstr 25th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, 25 to 28 April 2015.
26. Falagas ME, Skalidis T, Vardakas KZ, Legakis NJ. 2017. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals. J Antimicrob Chemother 72:1704 –1708. https://doi.org/10.1093/jac/dkx049.
27. Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. 2017. In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 study). Antimicrob Agents Chemother 61:e00093-17. https://doi.org/10.1128/AAC.00093-17.
28. Mushtaq S, Vickers A, Hussain A, Livermore D, Woodford N. 2017. In-vitro activity of cefiderocol (S-649266) against multidrug-resistant Enterobacteriaceae from the UK, abstr P1315. Abstr 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 22 to 25 April 2017.
29. Dobias J, Denervaud V, Poirel L, Nordmann P. 2017. Activity of the novel siderophore cephalosporin cefiderocol (S-649266) against Gram-negative pathogens, abstr OS0561. Abstr 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 22 to 25 April 2017.
30. Yamano Y, Tsuji M, Hackel M, Sahm D, Echols R. 2017. Mode of action of cefiderocol, a novel siderophore cephalosporin, active against highly resistant Gram-negative bacteria including carbapenem-resistant strains of Enterobacteriaceae and non-fermenting bacteria, abstr OS0750. Abstr 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 22 to 25 April 2017.
31. Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbath S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268–271. https:// doi.org/10.1111/j.1469-0691.2011.03570.x.
32. Tsuji M, Hackel M, Echols R, Sahm D, Yamano Y. 2016. MIC reproducibility of iron depleted cation adjusted-Mueller Hinton broth (ID-CAMHB) for microdilution testing of S-649266, a novel siderophore cephalosporin, abstr M-470. Abstr ASM Microbe 2016, Boston, MA, 16 to 20 June 2016. American Society of Microbiology, Washington, DC.
33. Katsube T, Wajima T, Ishibashi T, Ferreira JCA, Echols R. 2017. Pharmacokinetic/pharmacodynamics modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal function. Antimicrob Agents Chemother 61:e01381 -16. https://doi.org/10.1128/AAC.01381-16.
34. Tsuji M, Horyama T, Nakamura R, Echols R, Singley C, Rittenhouse S, Yamano Y. 2014. S-649266, a novel siderophore cephalosporin: efficacy against Klebsiella pneumoniae producing NDM-1 or KPC in rat lung infection model with recreated humanized exposure profile of 2 g dose with 1 or 3 h infusion, abstr 248. Abstr IDWeek 2014, Philadelphia, PA, 8 to 12 October 2014.
35. Monogue ML, Tsuji M, Yamano Y, Echols R, Nicolau DP. 2017. Efficacy of humanized exposures of cefiderocol (S-649266) against a diverse population of gram-negative bacteria in the murine thigh infection model. Antimicrob Agents Chemother 61:e01022-17. https://doi.org/10.1128/AAC.01022-17.
36. Allergan Plc. 2015. Avycaz package insert. Allergan, Plc, Dublin, Ireland. https://www.allergan.com/assets/pdf/avycaz_pi.
37. European Committee on Antimicrobial Susceptibility Testing. 2017. Breakpoint tables for interpretation of MICs and zone diameters, version 7.0, valid from 2017-01-01. European Committee on Antimicrobial Susceptibility Testing, Copenhagen Denmark. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_7.0 _Breakpoint_Tables.pdf.